Drug Combination Details
| General Information of the Combination (ID: C53856) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Lapatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| BT-20 | CVCL_0178 | Invasive breast carcinoma | Homo sapiens | |||
| MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
| In-vivo Model | Four to six week old female NOD-SCID mice received sub-cutaneous 17Beta-estradiol pellet (0.72 mg/day), 2 weeks prior to injection of 5 * 106 BT-474 cells resuspended in 4% Matrigel. | |||||
| Experimental
Result(s) |
Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-453 | CVCL_0418 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Downregulation and subcellular distribution of HER2 involved in MDA-MB-453 breast cancer cell apoptosis induced by lapatinib/celastrol combination. | |||||
